10-Q: Carisma Therapeutics Q2: Merger, Cash Crunch, Nasdaq Risk

Carisma Therapeutics reports Q2 2025 results, detailing a planned merger with OrthoCellix, significant operational wind-down, and ongoing Nasdaq compliance challenges.

Summary

• Reported a net loss of $9.774 million for the three months ended June 30, 2025, compared to $11.162 million for the same period in 2024.
• Reported a net loss of $19.040 million for the six months ended June 30, 2025, compared to $30.140 million for the same period in 2024.
• Cash and cash equivalents decreased to $1.999 million as of June 30, 2025, from $17.909 million at December 31, 2024.
• Accumulated deficit reached $324.6 million as of June 30, 2025.
• Entered into a Merger Agreement with OrthoCellix, Inc. on June 22, 2025, which, if completed, will result in OrthoCellix's business continuing as the Combined Company.
• Existing Carisma securityholders are expected to own approximately 10.0% of the outstanding shares of the Combined Company on a fully-diluted basis post-merger and concurrent investment.
• The merger values OrthoCellix at $135.0 million (subject to adjustment) and Carisma at $15.0 million (subject to net cash adjustment).
• An anticipated Concurrent Investment of $25.0 million is planned, with Ocugen, Inc. committing to purchase $5.0 million of shares.
• Implemented a cash preservation plan, reducing operations to identify strategic alternatives and prepare for an orderly wind-down, with no intention of resuming historical research and development activities.
• A workforce reduction on March 25, 2025, affected 37 employees, representing approximately 84% of the total workforce, incurring $4.2 million in termination benefits.
• Collaboration revenues were $0 for the three months ended June 30, 2025, and $3.729 million for the six months ended June 30, 2025, a significant decrease from prior periods.
• Moderna has nominated all 12 oncology research targets under the collaboration, and the company will no longer conduct additional research activities or receive further research funding from Moderna.
• The company faces Nasdaq non-compliance issues and was granted an extension until October 7, 2025, to meet listing requirements, including a $1.00 minimum bid price.
• Stockholders approved an amendment to the certificate of incorporation to effect a reverse stock split (1-for-10 to 1-for-50) to aid Nasdaq compliance.

Sentiment

Score: 2

Explanation: The company is in severe financial distress, evidenced by rapidly depleting cash, an accumulated deficit, and an explicit 'going concern' warning. The cessation of all R&D and an 84% workforce reduction indicate a complete pivot from its original business model. While a merger is planned, it involves substantial dilution for existing shareholders and carries significant risks, including potential failure and subsequent liquidation. Nasdaq delisting remains a high probability.

Positives

• Net loss decreased for both the three-month ($9.774 million vs. $11.162 million) and six-month ($19.040 million vs. $30.140 million) periods ended June 30, 2025, compared to the prior year, primarily due to reduced operating expenses from the wind-down.
• Entered into a Merger Agreement with OrthoCellix, Inc., providing a potential strategic path forward for the company and its assets.
• Moderna has nominated all 12 oncology research targets under the collaboration, indicating progress in that partnership and retaining potential for future milestone and royalty payments.
• Stockholders approved a reverse stock split, a necessary step to address Nasdaq listing compliance and potentially maintain public listing.
• Nasdaq granted an extension until October 7, 2025, to regain compliance with listing standards, offering a temporary reprieve.

Negatives

• Cash and cash equivalents significantly declined to $1.999 million as of June 30, 2025, from $17.909 million at December 31, 2024, indicating a rapid cash burn.
• Accumulated deficit of $324.6 million as of June 30, 2025, highlights a history of unprofitability.
• Substantial doubt exists about the company's ability to continue as a going concern, indicating severe financial distress.
• Operations have been drastically reduced to focus solely on strategic alternatives and wind-down, with no intention of resuming historical research and development activities.
• A significant workforce reduction (84% of total workforce) was implemented, incurring $4.2 million in termination benefits.
• Collaboration revenues plummeted to $0 for Q2 2025 (from $9.197 million in Q2 2024) and significantly decreased for the six-month period, reflecting the cessation of R&D services for Moderna.
• Incurred a $3.5 million loss on the sale of held-for-sale assets and a $0.9 million loss on the abandonment of an operating lease right-of-use asset during the six months ended June 30, 2025.
• Ongoing non-compliance with Nasdaq listing rules, with a hard deadline of October 7, 2025, and no assurance of meeting requirements.
• Current Carisma stockholders are expected to own only approximately 10.0% of the Combined Company post-merger, indicating substantial dilution.
• The merger is subject to various closing conditions, including stockholder approval and Nasdaq listing approval, with no guarantee of completion.
• If the merger fails, the board may pursue bankruptcy, liquidation, or dissolution, with no assurance of cash distribution to stockholders.

Risks

• The Exchange Ratio for the OrthoCellix Merger will not be adjusted based on Carisma's market price, potentially leading to a greater or lesser value than negotiated.
• Failure to obtain required stockholder approvals for the merger and concurrent investment could prevent the closing of the OrthoCellix Merger.
• If the Merger Agreement is terminated under specified circumstances, Carisma may be required to pay OrthoCellix a termination fee of $500,000, or OrthoCellix may be required to pay Carisma $750,000 plus up to $500,000 in expenses.
• Conditions to the OrthoCellix Merger may not be satisfied or waived, including Ocugen obtaining consent from its institutional lender, potentially delaying or preventing the merger.
• The Combined Company's stock may not be approved for listing on Nasdaq, or Carisma may be delisted prior to the merger's closing, impacting liquidity and capital raising.
• Carisma and OrthoCellix may mutually agree to waive the Nasdaq listing condition, resulting in the Combined Company's stock not being listed on Nasdaq post-merger.
• Certain material adverse effects (e.g., industry-wide changes) are excluded from termination rights, obligating completion of the merger despite adverse impacts.
• The Combined Company will likely need to raise additional capital, which may cause significant dilution to stockholders or restrict operations through debt covenants.
• Carisma stockholders will experience a significantly reduced ownership and voting interest (approximately 10.0%) in the Combined Company.
• Restrictions in the Merger Agreement may prevent Carisma from pursuing more favorable business combinations during the pendency of the OrthoCellix Merger.
• The lack of a public market for OrthoCellix's capital stock makes it difficult to evaluate its fair market value, potentially leading to an over or undervaluation in the merger.
• Potential lawsuits may be filed against Carisma or its directors arising out of the OrthoCellix Merger, which could delay or prevent closing.
• There is no assurance of successfully consummating the OrthoCellix Merger or identifying and completing any other strategic alternatives.
• Carisma has limited time and resources to complete the merger or another strategic alternative before depleting its cash resources and facing the Nasdaq Compliance Date.
• There is no assurance of successfully pursuing and consummating any asset monetization transactions.
• If the OrthoCellix Merger is not completed and no other strategic alternative is found, it is highly unlikely there will be cash available for distribution to stockholders.
• If the board elects to commence bankruptcy or liquidation proceedings, such actions may delay the wind-down, increase costs, and decrease any cash available for stockholders.
• The cash preservation plan, including significant workforce reductions, may cause difficulties, delays, or unexpected costs and could adversely affect the ability to consummate the merger.
• The company is substantially dependent on its remaining employees and consultants, whose loss could harm the ability to consummate the merger or other strategic alternatives.
• Changes in tax laws (e.g., IRA, OBBBA) or their interpretation could adversely affect the business and financial condition.
• The market price of Carisma's common stock is volatile and may drop further, exacerbated by low trading volume and uncertainties surrounding the merger and wind-down.
• The contemplated reverse stock split may not increase the stock price over the long-term or improve liquidity, and may result in stockholders owning odd lots.

Future Outlook

The company has no intention of resuming its historical research and development activities. Its future operations are highly dependent on the successful completion of the OrthoCellix Merger, after which OrthoCellix's business will continue as the Combined Company. Prior to the merger, the company will seek to monetize certain legacy assets. Current cash and cash equivalents are projected to sustain operations only into the fall of 2025 and not for more than one year, raising substantial doubt about its ability to continue as a going concern. If the merger fails, the board may pursue another strategic transaction, asset sale, or liquidation/dissolution. The company anticipates potential future milestone and royalty payments from the Moderna collaboration. Significant expenses related to the merger process are expected, regardless of completion. A reverse stock split is planned to address Nasdaq listing compliance, but its long-term effectiveness is uncertain.

Management Comments

• We currently have no intention of resuming our historical research and development activities.
• Our future operations are highly dependent on the success of the OrthoCellix Merger.
• Although we believe our current cash and cash equivalents are sufficient to sustain our operating expenses and capital expenditure requirements into the fall of 2025, we do not expect that our cash and cash equivalents will support our operations for more than one year following the date of this Quarterly Report on Form 10-Q.
• As a result of these conditions, substantial doubt exists about our ability to continue as a going concern.

Industry Context

The biotechnology industry is characterized by high R&D costs, lengthy development timelines, and significant regulatory hurdles. Carisma's strategic pivot, involving the cessation of internal R&D, a substantial workforce reduction, and a reverse merger, reflects the challenging capital environment and competitive pressures, particularly in specialized therapeutic areas like anti-HER2 treatments. This move is a common strategy for distressed biotech firms seeking a new operational path or for entities to acquire public listing status. While the collaboration with Moderna highlights the value of innovative platforms like CAR-M, Carisma's inability to independently fund further research underscores the intense capital demands of drug development.

Comparison to Industry Standards

• Carisma's cash runway, projected to last only 'into the fall of 2025' and 'not more than one year,' is significantly below the typical 12-18+ months sought by most biotech companies to fund ongoing R&D and operations.
• The complete cessation of internal R&D activities and an 84% workforce reduction are extreme measures, contrasting sharply with active biotech firms like Moderna (their partner) or other oncology/fibrosis developers (e.g., Gilead Sciences, Bristol Myers Squibb, Novartis) that continuously invest heavily in pipeline expansion.
• The proposed merger valuation, where Carisma is valued at $15.0 million compared to OrthoCellix's $135.0 million, indicates a substantial shift in control and value, reflecting Carisma's weakened financial position and the value attributed to OrthoCellix's assets. This is a common characteristic of reverse mergers where the public shell company has limited intrinsic value beyond its listing status.
• Facing Nasdaq delisting due to low bid price and market value is a common challenge for smaller, struggling public companies. The planned reverse stock split is a standard tactic to address this, but its long-term efficacy in maintaining listing and attracting investors is often uncertain, unlike the stable listing status of industry leaders.
• While the collaboration with Moderna is a positive, the cessation of R&D funding from Moderna and Carisma's inability to conduct further research activities under the agreement indicates a reduced role for Carisma in the partnership's active development phase, shifting its potential value to future milestones and royalties rather than active contribution, unlike fully engaged R&D partners.

Corporate Governance

Legal Proceedings

• No material legal matters or claims were a party to as of the date of this Quarterly Report on Form 10-Q.
• In negotiations with a vendor to determine total costs owed for research and development services, with an estimated liability of $1.9 million ($1.4 million in accounts payable, $0.5 million in accrued expenses).
• Potential for litigation or other claims related to a liquidation and dissolution of the company if the OrthoCellix Merger is not completed.

Related Party Transactions

• The company has a collaboration and license agreement with Moderna, which is a significant stockholder.

Stakeholder Impact

• Shareholders face significant dilution, with current securityholders expected to own only approximately 10.0% of the Combined Company post-merger.
• Shareholders are at high risk of losing all or a significant portion of their investment if the merger fails and the company proceeds with liquidation or dissolution.
• Employees have already experienced a drastic workforce reduction (84% of total workforce), with remaining employees critical for merger completion and wind-down activities.
• Creditors may face uncertainty regarding the full satisfaction of outstanding obligations in a potential liquidation scenario, as assets may need to be reserved for contingent liabilities.
• Moderna, as a significant stockholder and collaborator, will no longer receive R&D services from Carisma but retains potential for future milestone and royalty payments from the collaboration.
• OrthoCellix and its sole stockholder stand to gain a public listing and control approximately 90.0% of the Combined Company, assuming the merger and concurrent investment are successful.

Next Steps

• Complete the OrthoCellix Merger, subject to stockholder approval and other closing conditions.
• Seek to enter into transactions with third parties to monetize certain legacy assets prior to the completion of the OrthoCellix Merger.
• OrthoCellix and designated investors are to use commercially reasonable efforts to secure commitments for the $25.0 million Concurrent Investment by September 15, 2025.
• Ocugen, Inc. is in the process of seeking consent from its institutional lender for its $5.0 million investment in the Concurrent Investment.
• Effect a reverse stock split (ratio of 1-for-10 to 1-for-50) to increase the per-share closing bid price of common stock.
• Demonstrate compliance with Nasdaq Capital Market listing rules, including the $1.00 bid price rule, by October 7, 2025.
• Obtain Nasdaq approval for the listing of the shares of the Combined Company's common stock to be issued in connection with the OrthoCellix Merger.
• If the OrthoCellix Merger does not close, the board may elect to attempt another strategic transaction, sell remaining assets, or commence bankruptcy or liquidation proceedings.
• Evaluate the effect of recently issued accounting pronouncements (ASU 2023-09 and ASU 2024-03) on its disclosures and financial statements.

Key Dates

Recommendation

Carisma Therapeutics is in a highly precarious financial position, evidenced by its 'going concern' warning, rapidly dwindling cash, and accumulated deficit. The company has ceased all its historical R&D activities and undergone an 84% workforce reduction, effectively winding down its prior business. While a merger with OrthoCellix is planned, it involves extreme dilution for current shareholders (expected to own only 10% of the combined entity) and is subject to numerous risks and conditions, including potential failure. The company also faces imminent Nasdaq delisting if it cannot meet compliance requirements by October 7, 2025, despite a planned reverse stock split. If the merger fails, liquidation or bankruptcy is a strong possibility, with no assurance of any return for shareholders. The risks far outweigh any potential upside from the merger or contingent value rights, making the stock a strong sell for seasoned investors.

Keywords

Biotechnology, Merger, OrthoCellix, Nasdaq Compliance, Cash Preservation, Workforce Reduction, CAR-M, Oncology, Liver Fibrosis, Moderna Collaboration, Reverse Stock Split, Going Concern, SEC Filing, 10-Q, Financial Results, Strategic Alternatives, Dilution, Liquidation